Video 12 from Radcliffe Cardiology
The investigators on their own trials, recorded at the congresses, plus the sessions and guideline explainers. Embedded with Radcliffe's agreement; the framing is ours. See also the podcasts.
2025 ESC/EAS focused update: key changes in lipid management (Victoria Delgado, CLIMB 2026)
New Horizons in Dyslipidaemia 2026, session 3: lipoprotein(a) (Libby, Cho, Kronenberg, Mora)
AHA 2025: Lp(a) and ASCVD, translating causal evidence into practice (Michelle O'Donoghue)
ESC 2025: the focused update of the ESC/EAS dyslipidaemia guidelines, discussed (Roeters van Lennep, Van Spall)
ESC 2025: LipoaScreen, cascade screening for elevated Lp(a) in relatives (Jonas Brinck)
ACC.25: ALPACA, lepodisiran keeps Lp(a) down for 540 days after a single dose (Steven Nissen)
AHA 2024: KRAKEN, oral muvalaplin lowers Lp(a) by up to 85 percent (Stephen Nicholls)
AHA 2024: ALPACAR, zerlasiran in adults with elevated Lp(a) at high ASCVD risk (Steven Nissen)
AHA 2023: lepodisiran, an extended-duration siRNA against Lp(a) (Steven Nissen with CardioNerds)
AHA 2022: OCEAN(a)-DOSE, olpasiran cuts Lp(a) by more than 95 percent (Michelle O'Donoghue with CardioNerds)
